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Abstract
A3 adenosine receptors (ARs) play a pivotal role in the development of cancer and their activation is involved in the
inhibition of tumor growth. The effects of pulsed electromagnetic fields (PEMFs) on cancer have been controversially
discussed and the detailed mechanisms are not yet fully understood. In the past we have demonstrated that PEMFs
increased A2A and A3AR density and functionality in human neutrophils, human and bovine synoviocytes, and bovine
chondrocytes. In the same cells, PEMF exposure increased the anti-inflammatory effect mediated by A2A and/or A3ARs. The
primary aim of the present study was to evaluate if PEMF exposure potentiated the anti-tumor effect of A3ARs in PC12 rat
adrenal pheochromocytoma and U87MG human glioblastoma cell lines in comparison with rat cortical neurons. Saturation
binding assays and mRNA analysis revealed that PEMF exposure up-regulated A2A and A3ARs that are well coupled to
adenylate cyclase activity and cAMP production. The activation of A2A and A3ARs resulted in the decrease of nuclear factor-
kappa B (NF-kB) levels in tumor cells, whilst only A3ARs are involved in the increase of p53 expression. A3AR stimulation
mediated an inhibition of tumor cell proliferation evaluated by thymidine incorporation. An increase of cytotoxicity by
lactate dehydrogenase (LDH) release and apoptosis by caspase-3 activation in PC12 and U87MG cells, but not in cortical
neurons, was observed following A3AR activation. The effect of the A3AR agonist in tumor cells was enhanced in the
presence of PEMFs and blocked by using a well-known selective antagonist. Together these results demonstrated that PEMF
exposure significantly increases the anti-tumor effect modulated by A3ARs.
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Introduction
Increasing evidence demonstrates that adenosine affects nu-
merous pathophysiological processes including the regulation of
cell death and proliferation [1,2]. Adenosine interacts with four G-
protein coupled receptors named as A1,A 2A,A 2B and A3
adenosine receptors (ARs). A1 and A3ARs inhibit adenylate
cyclase activity and decrease cAMP production whilst A2A and
A2BARs exert an increase of cAMP accumulation [3]. The A3ARs
have been involved in the regulation of the cell cycle and both pro-
and antiapoptotic effects are closely associated with the level of
receptor activation [4]. A3ARs are involved in the modulation of
mitogen-activated protein kinase (MAPK) activity and in the
regulation of extracellular signal-regulated kinases (ERK1/2) [5].
It has been accepted that A3ARs are highly expressed in tumor
cells showing an important role in the development of cancer [6–
10]. The tumor cell growth inhibition was found in different
models as rat Nb2-11C and mouse Yac-1 lymphoma, B16-F10
melanoma, MCA sarcoma, PC3 prostate carcinoma, MIA-PaCa
pancreatic carcinoma, Hep-3B hepatocellular carcinoma and
HCT-116 colon carcinoma cells [11–14]. From the cellular point
of view, the A3AR agonist 2-chloro-N
6-(3-iodobenzyl)adenosine-
59-N-methyl-uronamide (Cl-IB-MECA) inhibited tumor growth
via de-regulation of the NF-kB signal transduction pathways,
resulting in apoptosis of tumor cells [10]. Pharmacological studies
demonstrated that A3AR agonists inhibited the growth of
melanoma cells, promoted the proliferation of bone marrow cells,
reduced cell viability in human breast cancer cells and induced
arrest of cell cycle progression in human lung cancer cells [15,16].
Moreover Cl-IB-MECA enhanced apoptosis via the modulation of
nuclear factor-kappa B (NF-kB) signaling pathway in thyroid
cancer cells and reduced the ability of prostate cancer cells to
migrate in vitro and metastasize in vivo [17,18]. In addition,
preclinical and Phase I studies showed that A3AR agonists are safe
and well tolerated in humans and thus may be considered possible
therapeutic agents for certain cancer diseases [5].
Large research activity has raised around the mechanisms of
interaction between low frequency magnetic fields and biological
systems [19]. Different physiological systems seem to be
influenced by electromagnetic field (EMF) exposure as revealed
from in vitro experiments in various cells or tissues [20–25].
Recently, it has been reported a correlation between EMF
exposure and neurodegenerative diseases as Alzheimer or
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fields (PEMFs) therapy significantly reduced post-operative pain
and narcotic use in the immediate post-operative period by
a mechanism that involve endogenous interleukin-1b (IL-1b)i n
the wound bed [29]. While some researchers associate EMF
exposure with carcinogenesis [30,31], other studies of experi-
mental models and human cancers have shown that EMF does
not increase the risk of several cancer types, and that treatment
with tumor-specific frequencies is feasible and well tolerated and
may have biological efficacy in patients with advanced tumors
[32–34]. Moreover, the exposure of female C3H/HeJ mice
bearing mammary adenocarcinoma to a frequency of 120 Hz at
intensities of 4 and 5 mT resulted in a significant reduction in
the tumor growth, which is a phenomenon associated with
angiogenesis inhibition [35]. The exposure of female athymic
nude mice with human breast cancer xenografts to a frequency
of 120 Hz with an intensity of 15 mT, either alone or in
combination with gamma radiation, resulted in decreased growth
and reduced vascularization of the tumors [36]. Similarly, the
effect of 50 Hz at 0.5 mT and 0.5 mT on the development of
chemically induced foci in rat livers showed a slight inhibition of
their formation [37]. In a recent work, the application of EMF
inhibits preneoplastic lesions chemically induced in the rat liver
through the reduction of cell proliferation, without altering the
apoptosis process [38]. Novel findings have demonstrate that the
magnetic field combined with X-Ray mediate a survival
improvement and tumor inhibition in hepatoma-implanted mice
[39]. In multidrug resistance (MDR) osteosarcoma cell line,
PEMFs increased doxorubicin binding ability to DNA and
inhibited cell growth, suggesting that PEMFs may be useful as
a local treatment for MDR osteosarcoma [40].
In the current study we investigated whether PEMFs modulate
the expression and the effect of A3ARs in different cells
represented by rat adrenal pheochromocytoma cells (PC12) and
human glioblastoma cell lines (U87MG) in comparison with rat
cortical neurons. Using these cellular models we highlighted the
effect of PEMFs on A3AR stimulation in NF-kB and p53
activation, cell proliferation, cytotoxicity and apoptosis. These
results indicate the possibility that the anti-tumor effect mediated
by A3ARs could be potentiated by a non invasive stimulus
represented by PEMFs.
Results
PEMFs up-regulated A2A and A3AR Density and
Expression
The first objective of the current study was to verify if affinity
and density of A1,A 2A,A 2B and A3ARs were affected by PEMFs in
rat cortical neurons, PC 12 and U87MG cells. In particular,
Table 1 reports the affinity (KD) and density (Bmax) values for ARs
in membranes or intact cells derived from rat cortical neurons,
U87MG cells and untreated or NGF-treated PC12 cells in the
absence and in the presence of PEMFs at 1.5 mT. Affinity values
of ARs were not affected by PEMF treatment in the cells examined
whilst A2A and A3AR density was significantly increased.
The PEMF treatment of primary culture of rat cortical neurons
at 1.5 mT induced an up-regulation of A2AAR density respect to
control conditions in both preparation such as membranes or
intact cells (Table 1). The exposure with PEMFs of untreated or
NGF-treated PC12 cells induced an up-regulation of A2AAR
density with a 2.20 or 2.10 fold of increase versus controls in
membrane preparation, respectively. The A2AAR up-regulation
Table 1. Affinity and density of A1,A 2A,A 2B and A3ARs in rat cortical neurons, untreated or NGF-treated PC12 cells and U87MG
membranes or cells in the absence or in the presence of PEMFs.
A1ARs A2AARs A2BARs A3ARs
KD Bmax KD Bmax KD Bmax KD Bmax
Rat Neurons
a 0.7860.06 180620 0.7460.05 5064 1.5260.11 3263 2.1160.14 3663
+ PEMFs 0.7360.05 178619 0.7960.06 10468* 1.5760.12 3063 2.1460.20 7667*
PC12
a 1.1260.10 4664 1.7160.09 152612 1.7260.16 6566 2.0560.18 9469
+ PEMFs 1.1760.11 4564 1.8560.14 335627* 1.7760.15 6266 2.1860.16 215620*
NGF-PC12
a 1.1160.09 4264 1.6560.15 164614 1.7360.15 6365 2.2160.15 10269
+ PEMFs 1.1360.08 4464 1.7260.06 345632* 1.7660.16 6464 2.3860.16 222621*
U87MG
a 1.0160.08 2862 1.5860.13 9169 1.8160.17 8569 2.1460.22 9368
+ PEMFs 1.0360.09 3062 1.6460.14 207619* 1.8360.16 8869 2.0160.19 216618*
Rat Neurons
b 0.7560.06 7.360.7 0.7260.06 2.460.2 1.6160.14 1.460.1 2.0260.17 1.760.1
+ PEMFs 0.7960.07 7.660.6 0.8160.07 4.660.5* 1.6860.11 1.260.1 2.1160.19 3.160.3*
PC12
b 1.0860.09 2.360.2 1.7760.11 7.660.5 1.7560.12 2.760.2 2.0160.15 3.460.2
+ PEMFs 1.1460.10 2.260.2 1.8960.13 17.161.2* 1.8160.10 2.560.2 2.1360.14 8.460.6*
NGF-PC12
b 1.1860.11 1.960.2 1.7160.14 8.460.7 1.7960.13 2.660.2 2.1960.13 3.760.4
+ PEMFs 1.1760.10 2.060.2 1.6960.10 19.462.1* 1.8460.15 2.460.2 2.2460.15 8.660.7*
U87MG
b 1.0760.09 1.560.1 1.6460.11 2.960.3 1.8560.14 2.860.2 2.0960.18 3.260.3
+ PEMFs 1.1160.10 1.660.1 1.7260.15 8.660.9* 1.7860.13 2.960.2 2.0560.17 8.360.8*
amembranes;
bintact cells. Affinity and density are expressed as KD, nM and Bmax, fmol/mg protein, respectively.
[
3H]-DPCPX saturation binding for A1ARs, [
3H]-ZM 241385 saturation binding for A2AARs, [
3H]-MRE2029F20 saturation binding for A2BARs, [
125I]AB-MECA saturation
binding for A3ARs. Data are expressed as mean (n=6) 6 SEM. Differences were considered significant at a value of p,0.01 vs the examined cells in the absence of
PEMFs (*).
doi:10.1371/journal.pone.0039317.t001
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values increased from 9169 (control condition) to 207619
(PEMFs treatment) fmol/mg protein. Similar results on A2AAR
up-regulation were also obtained performing the saturation
binding experiments with intact cells (Table 1).
PEMF treatment induced an up-regulation of A3ARs by 2.11 or
2.32 fold on rat cortical neurons and on U87MG cells respect to
control condition in membrane preparation, respectively (Table 1).
Similar effects were obtained exposing untreated or NGF-treated
PC12 cells with PEMFs at 1.5 mT. A3AR Bmax values increased
from 9469 (control condition) to 215620 (PEMF treatment)
fmol/mg protein in membrane from untreated PC12 cells. In
membrane preparation from NGF-treated PC12 cells A3AR
density increased from 10269 (control condition) to 222621
(PEMFs treatment) fmol/mg protein. Similarly, the A3AR up-
regulation were also observed performing the saturation binding
experiments with intact cells (Table 1).
Figure 1 shows the mRNA relative expression of A1,A 2A,A 2B
and A3ARs in rat cortical neurons, untreated or NGF-treated
PC12 cells and U87MG cells in the absence and in the presence of
PEMFs. Interestingly A2A and A3AR mRNA levels were up-
regulated after PEMF treatment confirming the increase of their
density found in saturation binding experiments (Table 1).
A2A and A3AR Stimulation and PEMFs Mediated
a Significant Modulation in cAMP Production
The A2AARs are coupled to stimulation of adenylate cyclase via
Gs proteins which mediates an increase of cAMP production. In
rat cortical neurons, U87MG cells and untreated or NGF-treated
PC12 cells, CGS 21680 at the 100 nM concentration was able to
mediate a significant increase in cAMP formation that is
potentiated in the cells treated with PEMFs. In all the
experimental conditions examined, SCH 58261 at the 1 mM
concentration was able to completely block the effect of CGS
21680. The effect of the A3AR agonist Cl-IB-MECA (100 nM)
was evaluated in the presence of 1 mM forskolin and 0.5 mM Ro
20-1724. This experimental condition was chosen for the low basal
levels (15–20 pmol cAMP per assay) which hamper the evaluation
of a direct inhibitory effect. Cl-IB-MECA mediated a significant
decrease of cAMP production and this effect was significantly
amplified in the cells treated with PEMFs (Fig. 2). Moreover, in all
the cells examined, the presence of MRS 1523 (1 mM) inhibited
the effect of Cl-IB-MECA confirming the involvement of A3ARs
in the modulation of cAMP production.
A2A and A3AR Stimulation Mediated a Significant
Inhibition of NF-kB Activation in the Presence of PEMFs
The effect of A2A or A3AR stimulation on NF-kB p65 subunit
activation was investigated in untreated or NGF-treated PC12
cells and U87MG cells respect to rat cortical neurons revealing the
capability of the A2A (CGS 21680) or A3AR (Cl-IB-MECA)
agonists to significantly decrease the activation of NF-kB in the
tumor cells after 24 hours of treatment (Fig. 3). PEMF exposure
was able to enhance the A2A or A3AR agonist-induced reduction
of NF-kB activation. The A3AR stimulation mediated a more
evident inhibition of NF-kB than A2A activation both in the
presence or in the absence of PEMFs. Interestingly, the
simultaneous treatment with A3AR agonist and PEMFs mediated
a significant inhibition of NF-kB levels respect to the A3AR
activation alone. The effect of these agonists was blocked by the
use of well known A2A or A3AR antagonists such as SCH 58261
and MRS 1523, respectively (Fig. 3).
Activation of A3AR in the Presence of PEMFs Increased
p53 levels Leading to Inhibition of Tumor Cell
Proliferation
The A2AAR agonist CGS 21680 was not able to modulate p53
protein levels neither in the absence nor in the presence of PEMFs
in the different cell types examined. Conversely, the A3AR agonist
Cl-IB-MECA (100 nM) mediated a significant increase of p53
expression in the tumor cell lines examined without affecting the
p53 levels of the rat control cortical neurons (Fig. 4). Although
PEMF exposure alone was not able to modify p53 expression, the
simultaneous treatment of tumor cells with PEMFs and Cl-IB-
MECA resulted in a further significant increase of p53 protein
levels in comparison with Cl-IB-MECA alone (p,0.05, Fig. 4B-
D).
To evaluate if the modulation of NF-kB and p53 was related to
regulation of tumor cell proliferation, a thymidine incorporation
assay was performed in the presence or in the absence of PEMFs.
In our experimental conditions the basal levels of [
3H]-thymidine
incorporation in rat cortical neurons, untreated or NGF-treated
PC12 and U87MG cells were 447642, 82286782, 856678,
95356844 cpm per sample, respectively. The results indicated
that neither CGS 21680 nor PEMFs (alone or in combination)
were able to significantly modulate cell proliferation (Fig. 5). The
stimulation of A3ARs by means of Cl-IB-MECA (100 nM)
mediated a significant inhibition of thymidine incorporation of
39%, 41% and 32% in untreated, NGF-treated PC12 cells and
U87MG cells, respectively. Notably, PEMF exposure potentiated
in a statistically significant way (p,0.05) the effect of Cl-IB-MECA
on tumor cell proliferation (Fig. 5B–D). Moreover, A3AR
stimulation, in the absence or in the presence of PEMFs, did not
affect thymidine incorporation in rat cortical neurons, suggesting
that the observed effect was selective for tumor cells (Fig. 5). The
direct role of A3ARs in mediating the effect of Cl-IB-MECA was
demonstrated by using a selective A3AR antagonist, MRS 1523,
that completely abrogated the agonist-induced regulation of p53
and cell proliferation (Figs. 4 and 5).
PEMF Exposure Enhanced the Cl-IB-MECA-induced Cell
Death and Apoptosis in Tumor Cells
Figure 6 shows the effect of A2A or A3AR stimulation on lactate
dehydrogenase (LDH) release (% of control in basal condition)
from rat cortical neurons, untreated or NFG-treated PC12 cells
and U87MG cells in the absence or in the presence of PEMF
exposure (1.5 mT). In all the examined cells, the presence of CGS
21680 (100 nM) was not able to modify the LDH release neither in
the absence nor in the presence of PEMFs. In rat cortical neurons
and tumor cells, PEMF exposure in basal condition was not able to
modulate LDH release. The A3AR agonist Cl-IB-MECA
(100 nM) mediated a cytotoxic effect in all the tumor cells
examined as demonstrated by the significant increase of LDH
release. Interestingly, the simultaneous presence of PEMFs
resulted in a further increase of LDH production mediated by
Cl-IB-MECA reaching values of 192%, 226% and 243% respect
to the basal condition in untreated, NGF-treated PC12 and
U87MG cells, respectively (Fig. 6B–D). To evaluate if the
synergistic effect of Cl-IB-MECA and PEMFs involved apoptotic
signals, the levels of active caspase-3 were evaluated. Among the
different treatment conditions, only the A3AR stimulation was able
to significantly increase the levels of active caspase-3 in all the
tumor cells, but not in rat control cortical neurons (Fig. 7).
Furthermore, PEMF exposure enhanced the pro-apoptotic effect
of Cl-IB-MECA in cancer cells obtaining an increase of 1.97, 2.64
and 3.24 fold respect to basal condition in untreated or NGF-
A3 Adenosine Receptors and PEMFs in Cancer Cells
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of a well known A3AR antagonist, MRS 1523, reverted the effect
of the agonist, suggesting a specific involvement of this receptor
subtype.
Discussion
Numerous studies have demonstrated the involvement of
A3ARs in the regulation of cell cycle, in pro- and anti-apoptotic
effects, in the reduction of cell viability and in the inhibition of
cancer growth [4,15–18]. In addition, preclinical and Phase I
studies showed that A3AR agonists are safe and well tolerated in
humans and thus may be considered possible therapeutic agents
for certain cancer diseases [5]. As reported in different works some
researchers associate EMF exposure with carcinogenesis [30,31],
while other studies have shown that EMF do not increase the risk
of several cancer types, and that the treatment with specific
frequencies is well tolerated and may have biological efficacy in
patients with advanced tumors [32–34]. At present, no data are
reported in literature on the effect of ARs and PEMF exposure in
in vitro or in vivo models of cancer, even if some results have
demonstrated the potentiation of the anti-inflammatory effects of
ARs by the presence of PEMFs [22–25].
In this paper we have combined the role of A3ARs as a target
for cancer with the growing observation that PEMFs may have
beneficial effects in the modulation of physiological processes
associated with tumor cell signaling. More specifically the current
experiments demonstrate that PEMFs modulate the expression
Figure 1. PEMFs increased A2A and A3AR mRNA levels. Relative mRNA expression of A1,A 2A,A 2B and A3ARs in rat cortical neurons, untreated
or NGF-treated PC12 cells and U87MG cells in the absence or in the presence of PEMFs. Values are the mean (n=6) 6 SEM.
doi:10.1371/journal.pone.0039317.g001
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represented by PC12 and U87MG cells in comparison with rat
cortical neurons. It is well reported that cell lines are useful in
pharmacological studies because they offer an opportunity to study
signal transduction and regulation of receptors under more
controlled conditions than in native cells or tissues [41]. Moreover,
we have treated PC 12 cells with NGF to evaluate the functional
responses of tumor cells differentiated in neuron-like cells. Using
these cellular models we highlighted the combined effect of PEMF
exposure and A3AR stimulation in different physiological
responses such as NF-kB and p53 activation, cell proliferation,
cytotoxicity and apoptosis.
Figure 2. cAMP modulation by PEMFs up-regulated A2A and A3ARs. Effect of a well-known A2AAR agonist and antagonist (CGS 21680,
100 nM; SCH 58261, 1 mM) or A3AR agonist and antagonist (Cl-IB-MECA, 100 nM; MRS 1523, 1 mM) in rat cortical neurons, untreated or NGF-treated
PC12 cells and U87MG cells in the absence or in the presence of PEMFs on cAMP production. Values are the mean (n=6) 6 SEM.
doi:10.1371/journal.pone.0039317.g002
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A3AR mRNA and density in tumor cells as well as in rat cortical
neurons. Saturation binding experiments of A2A and A3ARs
performed after PEMF exposure in rat cortical neurons, in
untreated or NGF-treated PC12 cells and in U87MG cells
(membranes or intact cells) revealed a significant increase in
Bmax values in comparison with unexposed cells suggesting the
modulation of PEMF treatment on the receptor density. These
Figure 3. Inhibition of NF-kB activation by the co-presence of PEMFs and A2A or A3AR agonists. Effect of a well-known A2AAR agonist
and antagonist (CGS 21680, 100 nM; SCH 58261, 1 mM) or A3AR agonist and antagonist (Cl-IB-MECA, 100 nM; MRS 1523, 1 mM) in rat cortical neurons,
untreated or NGF-treated PC12 cells and U87MG cells in the absence or in the presence of PEMFs on NF-kB activation which was evaluated by
detecting phosphorylated p65 proteins in nuclear extracts. Values are the mean (n=6) 6 SEM.
doi:10.1371/journal.pone.0039317.g003
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PEMFs are able to up-regulate A2A and A3AR density and
functionality in human neutrophils, human and bovine synovio-
cytes, and bovine chondrocytes [22–25]. Moreover these results
are closely associated with recent data showing the increase of
A2AARs in rat cortical neurons following PEMF exposure [42]. At
the present, the mechanisms of PEMF action are still poorly
defined even if at a molecular level could involve modifications of
receptor recycling to the cell membrane as well as a regulatory
effect at a transcriptional level, as suggested by the increase of A2A
and A3AR mRNA following PEMF exposure.
To investigate if the up-regulation of A2A and A3ARs was
associated with a high functionality of these receptors, different
cellular responses have been studied. First of all we have evaluated
the effect of well known adenosine agonists such as CGS 21680
and Cl-IB-MECA on cAMP accumulation. In the cell lines
investigated the stimulation of CGS 21680 on A2AARs was
increased after the treatment with PEMFs. Similarly, the in-
Figure 4. A3AR agonist and PEMFs increased p53 levels. Effect of a well-known A2AAR agonist and antagonist (CGS 21680, 100 nM; SCH
58261, 1 mM) or A3AR agonist and antagonist (Cl-IB-MECA, 100 nM; MRS 1523, 1 mM) in rat cortical neurons, untreated or NGF-treated PC12 cells and
U87MG cells in the absence or in the presence of PEMFs on p53 levels. Values are the mean (n=6) 6 SEM.
doi:10.1371/journal.pone.0039317.g004
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exposure in primary rat cortical neurons, untreated or NGF-
treated PC12 cells and U87MG cells suggesting that the increase
of the receptors is associated with an increase of receptor
functionality. Because of the close association between NF-kB
signal transduction pathways and a wide range of cellular
processes including proliferation, survival and apoptosis we
analyzed the role of A2A and A3ARs in the absence and in the
Figure 5. Synergistic effect of A3AR stimulation and PEMFs in the inhibition of tumor cell proliferation. Effect of a well-known A2AAR
agonist and antagonist (CGS 21680, 100 nM; SCH 58261, 1 mM) or A3AR agonist and antagonist (Cl-IB-MECA, 100 nM; MRS 1523, 1 mM) in rat cortical
neurons, untreated or NGF-treated PC12 cells and U87MG cells in the absence or in the presence of PEMFs on thymidine incorporation. Values are the
mean (n=6) 6 SEM.
doi:10.1371/journal.pone.0039317.g005
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exposure was able to enhance the reduction of NF-kB induced by
A2A and A3AR stimulation. Since the crosstalk between NF-kB
and p53 oncosuppressor protein is recognized to have a crucial
role in the development of cancer [43], we have evaluated the
effect of A2A and A3AR activation and PEMFs exposure on p53
protein levels. In tumor cells, but not in rat cortical neurons, the
A3AR agonist Cl-IB-MECA mediated an increase of p53 levels, an
effect that was enhanced by the presence of PEMFs. These results
are in agreement with those found in a recent work, showing that
an A3AR agonist inhibited prostate cancer cells proliferation and
induced G1 cell cycle arrest through the p53 induction [44]. To
evaluate if the regulation of these fundamental factors was related
with the modulation of tumor cell proliferation, a thymidine
incorporation assay was performed. An inhibitory effect of Cl-IB-
MECA on cell proliferation was found in tumor cells confirming
the involvement of A3AR activation in blocking tumor de-
velopment and was much more evident in the presence of PEMF
Figure 6. Cytotoxicity of A3AR activation and PEMFs in tumor cells. Effect of a well-known A2AAR agonist and antagonist (CGS 21680,
100 nM; SCH 58261, 1 mM) or A3AR agonist and antagonist (Cl-IB-MECA, 100 nM; MRS 1523, 1 mM) in rat cortical neurons, untreated or NGF-treated
PC12 cells and U87MG cells in the absence or in the presence of PEMFs on lactate dehydrogenase (LDH) levels. Values are the mean (n=6) 6 SEM.
doi:10.1371/journal.pone.0039317.g006
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in the tumor cells examined. The PEMF treatment did not modify
the proliferation in cortical neurons in the absence or in the
presence of AR stimulation even if the low proliferative index
could represent a drawback. In addition, these effects were
abrogated by the presence of A3AR antagonist suggesting the
direct involvement of this specific AR subtype. Nowadays, the
anti-proliferative effect of Cl-IB-MECA has been extensively
investigated with conflicting results due to the tissues or cells
analyzed. For example it has been demonstrated that Cl-IB-
MECA derivatives mediate a reduction of cell proliferation
through cell cycle arrest in human lung cancer cells suggesting
Figure 7. PEMF exposure enhanced the A3AR agonist-induced apoptosis in tumor cells. Effect of a well-known A2AAR agonist and
antagonist (CGS 21680, 100 nM; SCH 58261, 1 mM) or A3AR agonist and antagonist (Cl-IB-MECA, 100 nM; MRS 1523, 1 mM) in rat cortical neurons,
untreated or NGF-treated PC12 cells and U87MG cells in the absence or in the presence of PEMFs on active caspase 3 levels. Values are the mean
(n=6) 6 SEM.
doi:10.1371/journal.pone.0039317.g007
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cell migration [45]. We have also found that the A3AR agonist Cl-
IB-MECA mediated a cytotoxic effect in the different tumor cells
examined as demonstrated by the significant increase of LDH
release. The effect of A3AR stimulation on LDH release was
potentiated by PEMF exposure in untreated or NGF treated PC12
cells and in U87MG cells. Notably, no cytotoxic effect of Cl-IB-
MECA was found in rat cortical neurons, suggesting that this
effect could be associated to the tumor cells. These results are in
agreement with those previously reported demonstrating that
A3AR agonists potentiate the cytotoxic effect of the chemother-
apeutic agents in colon carcinoma cells [46]. In order to evaluate if
the observed effect of A3AR activation on tumor cell signaling and
death also involved apoptotic events, active caspase-3 levels were
investigated following the treatment with AR agonists in the
presence or in the absence of PEMF exposure. Neither CGS
21680 nor Cl-IB-MECA, alone or in combination with PEMFs,
were able to affect active caspase-3 levels in rat cortical neurons.
Interestingly, in tumor cells, Cl-IB-MECA, but not CGS 21680
was able to increase caspase-3 levels, an effect that was enhanced
by PEMF exposure, suggesting the synergistic role of A3AR
stimulation and PEMFs in the induction of apoptosis. These results
are consistent with those recently reported showing that the A3AR
agonist IB-MECA induced apoptosis in rat prostate cancer cell
lines and in the human metastatic androgen-independent prostate
cancer cell line [18]. All these data confirm previous papers where
in different tumors it has been found a direct involvement of A3AR
expression and functionality [14,47].
Despite the increasing amount of experimental data on PEMFs,
controversial effects have been reported probably due to the
various systems and apparatus used in in vivo or in vitro experiments.
In particular, the different physical variables such as frequency,
intensity and the waveform could be used on empirical basis. In
this study, we have used a well characterized PEMF exposure
system, based on rational driven methodology, which was able to
modulate in various non-tumor cell types, the expression and
functionality of ARs as previously reported [22–25,42,48]. In vitro
experiments on different tumor cell lines have suggested that
PEMF application combined with anticancer drugs will be very
effective as non invasive applications to tumor therapy [49]. In an
in vivo animal model the application of low frequency EMF inhibits
preneoplastic lesions chemically induced in the rat liver through
the reduction of cell proliferation [50]. Recently, in clinical studies
with various types of cancers by using a non-invasive feedback
method to identify tumor-specific frequencies and to test the
feasibility of administering such frequencies to patients with
advanced cancer were performed and may lead to the discovery of
novel pathways controlling cancer growth [34].
Previous in vitro assays have reported that A3AR agonists exert
a differential effect on normal and tumor cells. In normal cells, the
agonists induce the production of growth factors and in tumor
cells, the agonists induce apoptosis and tumor growth inhibition
via deregulation of the NF-kB and the Wnt signaling pathways [5–
7,11,12]. Our results are in agreement with these data and confirm
the dual role of A3ARs raising the question about the mechanism
of this differential effect. A possible explanation could be related to
the different expression of crucial regulatory factor in tumor cells.
It is well known that NF-kB is highly expressed in tumor cells
where its constitutive activation appears to affect cancer cell
survival by promoting anti-apoptotic genes expression [51,52]. In
our study, the low concentration of Cl-IB-MECA was most likely
sufficient to inhibit NF-kB in tumor cells without affecting this
pathway in control cells. Analogously, the effect of A3AR
stimulation on dysregulated p53 protein in tumor cells could be
on the basis of the different responses observed respect to the
control cells. PEMF exposure potentiated these effects in tumor
cells without increase the concentration of the A3AR agonist.
From the pharmacological point of view, a possible advantage of
the combination of low dose agonist and of a localized external
PEMF therapy could be the reduction of the risk of adverse or
systemic side effects that increase dramatically when the drugs are
administered at high dose.
These results indicate the possibility that the anti-tumor effect
mediated by A3ARs could be potentiated by a non-invasive
stimulus represented by PEMFs, allowing to use of low concentra-
tions of the agonist limiting its potential side effects. The pro-
apoptotic and anti-proliferative effect promoted by the A3AR
agonist Cl-IB-MECA seems to be specific for tumor cells without
affecting rat primary neurons. Future in vivo studies are therefore
warranted to better investigate the synergistic interaction between
A3ARs and PEMF exposure and to further confirm the efficacy of
this treatment as well as to evaluate adverse effects.
Materials and Methods
Preparation of Rat Brain Cortical Neurons, PC12 and
U87MG Cells
Primary rat cortical cells isolated from day-18 rat embryos
containing minimum amount of astrocytes and other glial cells
were purchased from Invitrogen (Carlsbad, CA, USA). These
highly pure cells were grown in Neurobasal Medium containing
B27 supplements (Invitrogen). Before using, cells were washed
twice with serum-free medium and treatments were carried out in
Neurobasal medium without phenol red and B27 supplements
without anti-oxidants [53].
Rat pheochromocytoma (PC12) cells were purchased from
American Type Culture Collection (Manassas, VA, USA) and
were maintained in DMEM medium supplemented with 5% FBS,
10% horse serum, L-glutamine (2 mM), penicillin (100 U/ml) and
streptomycin (100 mg/ml) in a humidified atmosphere (5% CO2)
at 37uC. Cells were subcultured three times a week at a density of
500000/ml. Differentiation was achieved by treatment with
50 ng/ml nerve growth factor (NGF, Sigma, St Louis, MO) for
1 week [54].
U87MG (malignant glioma) cells were purchased from Amer-
ican Type Culture Collection (Manassas, VA, USA). U87MG cells
were maintained in Dulbecco’s modified Eagle’s medium/Ham’s
F12 medium (DMEM/F12 medium) with 20% fetal calf serum,
2 mM l-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin
in a humidified atmosphere (5% CO2)a t3 7 uC [55].
Electromagnetic Field Exposure System
Rat cortical neurons, untreated or NGF-treated PC12 and
U87MG cells were exposed to PEMFs generated by a pair of
rectangular horizontal coils (14 cm 623 cm), each made of 1400
turns of copper wire placed opposite to each other. The culture
was placed between this pair of coils so that the plane of the coils
was perpendicular to the culture flasks. The coils were powered by
the PEMF generator system (IGEA, Carpi, Italy) used in previous
studies [22–25], which produced a pulsed signal with the following
parameters: pulse duration of 1.3 ms and frequency of 75 Hz,
yielding a 0.1 duty cycle. The peak intensity of the magnetic field
and peak intensity of the induced electric voltage were detected in
air between two coils from one side to the other, at the level of the
culture flasks. The peak values measured between two coils in air
had a maximum variation of 1% in the whole area in which the
culture flasks were placed. The dimensions of the flasks were
9.2 cm 68.2 cm with 10 ml of medium. The peak intensity of the
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Hall probe (HTD61-0608-05-T, F.W. Bell, Sypris Solutions,
Louisville, KY) of a gaussmeter (DG500, Laboratorio Elettrofisico,
Milan, Italy) with a reading sensitivity of 0.2%. The corresponding
peak amplitude of the induced electric voltage was 2.0 6 0.5 mV.
It was detected using a standard coil probe (50 turns, 0.5 cm
internal diameter of the coil probe, 0.2 mm copper diameter) and
the temporal pattern of the signal was displayed using a digital
oscilloscope (Le Croy, Chestnut Ridge, NY). The shape of the
induced electric voltage and its impulse length were kept constant.
Cell Treatment and Preparation
The primary rat cortical cells, PC 12 and U87MG cells were
also treated with well known A2A and A3AR agonists such as 2-[p-
(2-carboxyethyl)-phenethylamino]-59-N-ethylcarboxamido-adeno-
sine (CGS 21680, 100 nM, Sigma) and 2-chloro-N
6-(3-iodobenzyl)
adenosine-59-N-methyl-uronamide (Cl-IB-MECA, 100 nM, To-
cris, Bristol, UK) in the absence or in the presence of the selective
A2A and A3AR antagonists 5-amino-7-(phenylethyl)-2-(2-furyl)-
pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (SCH 58261,
1 mM, Tocris) and 3-Propyl-6-ethyl-5-[(ethylthio) carbonyl]-2
phenyl-4-propyl-3-pyridine carboxylate (MRS 1523, 1 mM, Sig-
ma), respectively. The primary rat cortical cells, PC 12 and
U87MG cells were then incubated at 37uC for 24 hours in the
presence or in the absence of PEMFs before the A1,A 2A,A 2B and
A3AR saturation binding experiments and functional assays. No
change of temperature was measured during time of PEMF
treatment. Membranes were also prepared from the cells described
above and were used to evaluate AR binding parameters. Briefly,
the cells were harvested by scraping from the plates, homogenized
with a Polytron (Kinematica, Bohemia, NY, USA) and the
membranes were then collected by centrifugation at 400006g for
15 min at 4uC. The protein concentration was determined
according to a Bio-Rad method with bovine albumin as reference
standard [22–24]. Saturation binding experiments were performed
by using intact cells or membranes from rat cortical neurons, PC
12 and U87MG cells.
Saturation Binding Experiments for A1,A 2A,A 2B and A3
Adenosine Receptors
Saturation binding experiments to A1ARs were performed
according to the method previously described using [
3H]-1,3-
dipropyl-8-cyclopentyl-xanthine ([
3H]-DPCPX, specific activity
120 Ci/mmol; Perkin Elmer Life and Analytical Sciences, Boston,
MA, USA) as radioligand [56]. The membranes (100 mgo f
protein/assay) with 8 to 10 concentrations of the radioligand [
3H]-
DPCPX (0.1–10 nM) were incubated in Tris HCl 50 mM,
pH 7.4, for 90 min at 4uC. Non specific binding was determined
in the presence of DPCPX 1 mM.
Saturation binding experiments to A2AARs were performed by
using [
3H]-4-(2-[7-amino-2-(2-furyl) [1,2,4] triazolo[2,3-a] [1,3,5]
triazin-5-yl- amino]ethyl ([
3H]-ZM 241385, specific activity
27.4 Ci/mmol; American Radiolabeled Chemicals Inc, Saint
Louis, MO, USA) as radioligand [22,41]. The membranes
(100 mg of protein/assay) were incubated for 60 min at 4uC with
8 to 10 concentrations of the radioligand [
3H]-ZM 241385 (0.1–
20 nM) and Tris HCl 50 mM, MgCl2 10 mM, pH 7.4. Non
specific binding was determined in the presence of ZM 241385
1 mM.
Saturation binding experiments to A2BARs were analyzed using
[
3H]-MRE 2029F20 ([
3H]-N-benzo [1,3]dioxol-5-yl-2-[5-(2,6-
dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methy-
1H-pyrazol-3-yl-oxy]-acetamide, specific activity 123 Ci/mmol,
GE Healthcare, UK) as radioligand [57]. Cell membranes (80 mg
of protein/assay) and [
3H]-MRE 2029F20 (0.1–20 nM) were
incubated for 60 min at 4uC and non specific binding was
determined in the presence of MRE 2029F20 (1 mM).
Saturation binding experiments to A3ARs were assessed using
[
125I]-AB-MECA ([
125I]-4-aminobenzyl-59-N-methylcarboxami-
doadenosine, specific activity 2000 Ci/mmol, Perkin Elmer) as
radioligand [56]. The membranes (50 mg of protein/assay) with
[
125I]-AB-MECA (0.1-10 nM) were incubated at 37uC for 60 min
and R-PIA (R-N
6-phenylisopropyl adenosine) 50 mM was used to
evaluate non specific binding.
Saturation binding experiments were also performed in intact
cells derived from the cell lines examined (10
6 cells/sample) with
an incubation time of 120 min for A1,A 2A and A2B ARs and
60 min for A3ARs at the temperature of 37uC.
Bound and free radioactivity were separated by filtering the
assay mixture through Whatman GF/B glass fibre filters by use of
a Brandel cell harvester (Brandel Instruments, USA). The filter
bound radioactivity was counted by Scintillation Counter Packard
Tri Carb 2810 TR (Perkin Elmer, USA).
Real-Time Quantitative Polymerase Chain Reaction (RT-
PCR) Experiments
Total cytoplasmic RNA was extracted from primary rat cortical
cells, PC12 and U87MG cells by the acid guanidinium thiocyanate
phenol method. Quantitative RT-PCR assays of A1,A 2A, A2B and
A3AR mRNAs were carried out using gene-specific fluorescently
labelled TaqMan MGB probe (minor groove binder) in a ABI
Prism 7700 Sequence Detection System (Applied Biosystems,
Warrington Cheshire, UK [58]. For the RT-PCR of A1,A 2A, A2B
and A3ARs the assays-on-demand
TM Gene expression Products
NM 000674, NM 000675, NM 000676 and NM 000677 were
used respectively. For the RT-PCR of the reference gene, the
endogenous control human b-actin kits was used, and the probe
was fluorescent-labeled with VIC
TM (Applied Biosystems, Monza,
Italy).
cAMP Production Assays
The rat cortical cells, PC12 and U87MG cells (10
6 cells per
sample) were suspended in 0.5 ml incubation mixture Krebs
Ringer phosphate buffer, containing 1.0 IU/ml adenosine de-
aminase (Sigma) and preincubated for 10 min in a shaking bath at
37uC. To better investigate the inhibitory effect of Cl-IB-MECA,
the cells were also incubated with forskolin (1 mM) and/or
0.5 mM of 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (Ro
20-1724) as phosphodiesterase inhibitor. The effect of CGS 21680
or Cl-IB-MECA was also evaluated in the presence of selected
antagonists such as SCH 58261 or MRS 1523 at 1 mM
concentration. The final aqueous solution was tested to evaluate
cAMP levels by using a competition protein binding assay with
[
3H]-cAMP, trizma base 100 mM, aminophylline 8.0 mM,
mercaptoethanol 6.0 mM, pH 7.4 [24]. At the end of the
incubation time (150 min at 4uC) and after the addition of
charchoal the samples were centrifuged at 20006g for 10 min and
the clear supernatant was counted in a liquid Scintillation Counter
Tri Carb Packard 2810 TR (Perkin-Elmer).
NF-kB Activation Assays
Nuclear extracts from the examined cells (primary rat cortical
cells, PC12 and U87MG cells) were obtained by using a nuclear
extract kit (Active Motif, Carlsbad, USA) according to the
manufacturer instructions. The NF-kB activation was evaluated
by detecting phosphorylated p65 proteins in nuclear extracts by
using the TransAM NF-kB kit (Active Motif). Phosphorylated NF-
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containing the NF-kB consensus site (59-GGGACTTTCC-39).
The primary antibody used to detect NF-kB recognized an epitope
in the subunits that is accessible only when it is activated and
bound to its DNA target. A horseradish peroxidase (HRP)-
conjugated secondary antibody provided a sensitive colorimetric
readout that was quantified by spectrophotometry at 450 nm
wavelength [58].
p53 ELISA Assay
For the detection of p53, the pan p53 ELISA kit (Roche
Molecular Biochemicals, Germany) was used in primary rat
cortical cells, PC12 and U87MG cells. Briefly, cell lysate and
biotinylated mouse monoclonal antibody were placed in 96 well
microtiter plates coated with mouse monoclonal antibody specific
for human p53, and were incubated for 2 hours at room
temperature. After removing unbound material by washing with
PBS, horseradish peroxidase conjugated streptavidin was added to
bind to the antibodies. The absorbance in each well was measured
at 450 nm, and concentrations of p53 were determinate by
interpolating from standard curves obtained with known concen-
trations of p53 protein [59].
Cell Proliferation Assays
All the cells examined, in the different conditions described
above, were seeded (10
5/cells per well) in fresh medium with
1 mCi/ml [
3H]-Thymidine for 24 hours in Dulbecco’s modified
Eagle’s medium containing 10% fetal calf serum, penicillin (100
units/ml), streptomycin (100 mg/ml). After 24 hours of labeling,
cells were trypsinized, dispensed in four wells of a 96-well plate,
and filtered through Whatman GF/C glass fiber filters using
a Micro-Mate 196 cell harvester (Perkin Elmer). The filter bound
radioactivity was counted on Top Count Microplate Scintillation
Counter with Micro Scint 20 [60].
Lactate Dehydrogenase Assay
LDH is a soluble cytosolic enzyme that is released into the
culture medium following loss of membrane integrity resulting
from either apoptosis or necrosis. LDH activity can be used as an
indicator of cell membrane integrity and serves as general meaning
to assess cytotoxicity resulting from chemical compounds or
environmental toxic factors [53].
LDH activity present in the culture medium was evaluated
using a coupled two-step reaction. In the first step, LDH catalyzes
the reduction of NAD
+ to NADH and H
+ by oxidation of lactate
to pyruvate. In the second step of the reaction, diaphorase uses the
newly-formed NADH and H
+ to catalyze the reduction of
a tetrazolium salt to highly-colored formazan which absorbs
strongly at 490–520 nm.
After 24 hours following treatment of the cells (primary rat
cortical cells, PC12 and U87MG cells), 100 ml of supernatant per
well was harvested and transferred into a new 96-well, flat-bottom
plate. LDH substrate (100 ml) was added to each well and
incubated for 30 min at room temperature protected from light.
The absorbance of the samples was measured at 490 mm on
spectrophotomer [58].
Apoptosis Assay
Apoptosis assay was performed evaluating active caspase-3
levels after the treatment of the cells with A2A or A3AR ligands
and/or PEMF exposure. After 24 hours, the cells were treated
with biotin-ZVKD-fmk inhibitor (10 mM) for one hour at room
temperature. After discarding the culture media, cells were rinsed
with PBS and the extraction buffer containing protease inhibitors
was added to prepare cell extracts. After two hours of incubation
at room temperature 100 ml of samples were transferred into
a microplate pre-coated with a monoclonal antibody specific for
caspase-3. After washing, 100 ml of streptavidin caspase-3
conjugated to horseradish peroxidases that binds to the biotin of
the inhibitor were added. Following the wash, the substrate
solution was added to the wells for 30 min and stop solution was
used to block the reaction. The optical density was determined
using a microplate reader set to 450 nm [58].
Statistical Analysis
Dissociation equilibrium constants for saturation binding,
affinity or KD values, as well as the maximum densities of specific
binding sites, Bmax, were calculated for a system of one or two-
binding site populations by non-linear curve fitting using the
program Ligand (Kell Biosoft, Ferguson, MO) [58]. Analysis of
data was performed by one-way analysis of variance. Differences
between the groups were analyzed with the unpaired t-test and
were considered significant at a value of p,0.05. All experimental
data are reported as mean6SEM of 6 independent experiments.
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